News|Articles|December 9, 2024

NGS-Based Viral Safety Testing for ATMPs: Mandatory or Just an Option?

Newsletter

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe

Related Content

Characterizing AAVs

ByWaters Corporation

September 2nd 2026

Sponsored Content

Streamlined Characterization of Recombinant AAVs via Charge Detection Mass Spectrometry: Insights from the USP AAV8 Reference Standards

ByWaters Corporation

September 2nd 2026

Sponsored Content

Quantifying quality attributes of AAV gene therapy vectors by SEC-MALS-UV-dRI

ByWaters Corporation

September 2nd 2026

Sponsored Content

Real-time monitoring and control of AAV chromatographic enrichment by RT-MALS

ByWaters Corporation

September 2nd 2026

Sponsored Content

Viral Vector Quality: No Estimates. Only Evidence

ByWaters Corporation

September 2nd 2026

Sponsored Content